{"entity":{"id":"nct06468358","kind":"trial","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of LB1410 and LB4330 in advanced solid tumours, run by L & L Bio Co., Ltd., Ningbo, China, now recruiting.","summary":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06468358 by L & L Bio Co., Ltd., Ningbo, China, with 194 participants planned, started 2024-06-19 and due to reach its primary completion in 2026-12-30. Interventions recorded: LB1410 and LB4330.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06468358","url":"https://clinicaltrials.gov/study/NCT06468358"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lb1410","lb4330"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06468358","phase":"1/2","setting":"A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"L & L Bio Co., Ltd., Ningbo, China","enrolled":194,"outcomes":[]},"route":"/trials/nct06468358/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lb1410","kind":"drug","name":"LB1410","route":"/drugs/lb1410/"},{"id":"lb4330","kind":"drug","name":"LB4330","route":"/drugs/lb4330/"}]}}